Precision medicine in myeloma: Challenges in defining an actionable approach

Publication date: Available online 23 June 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Verónica González-Calle, Niamh Keane, Esteban Braggio, Rafael Fonseca Recently, large sequencing studies have provided insights into the mutational landscape of multiple myeloma (MM), identifying actionable mutations and giving a precious opportunity for exploring new targeted therapies. The main goal of precision medicine, matching patients with the right drug, seems to be closer than ever. However, no targeted therapies in MM are approved yet. Several clinical trials testing targeted drugs and enrolling MM patients are currently ongoing and will provide predictive biomarkers that might support clinical decision-making. In this review we evaluate the evidence supporting the implementation of precision medicine in MM and we discuss the challenges that should to be dealt with in this imminent and promising new era.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research